The FDA approved Eli Lilly’s once-weekly basal insulin pen, Onswik, for patients with type 2 diabetes, setting up direct competition with Novo Nordisk’s weekly insulin franchise. Lilly has positioned Onswik as a longer-acting alternative to daily basal injections. The approval intensifies pressure on pricing, patient uptake, and payer coverage decisions as insulins with extended dosing intervals aim to improve adherence and simplify long-term diabetes management. For clinicians, switching between weekly options also raises questions about titration strategy, hypoglycemia risk, and real-world persistence. The competitive landscape also affects manufacturing and supply planning for multinational insulin makers, especially as weekly formulations scale beyond initial launch populations.